Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NNVC Stock Forecast 2026-2027
$1.26
Current Price
$27.10M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NNVC Price Targets
+455.6%
To High Target of $7.00
+415.9%
To Median Target of $6.50
+376.2%
To Low Target of $6.00
NNVC Price Momentum
+7.7%
1 Week Change
+22.3%
1 Month Change
-6.0%
1 Year Change
+11.5%
Year-to-Date Change
-43.5%
From 52W High of $2.23
+48.2%
From 52W Low of $0.85
📊 TOP ANALYST CALLS
Did NNVC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if NanoViricides is one of their latest high-conviction picks.
Latest NNVC Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, NNVC has a bullish consensus with a median price target of $6.50 (ranging from $6.00 to $7.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.26, the median forecast implies a 415.9% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NNVC Analyst Ratings
1
Buy
0
Hold
0
Sell
NNVC Price Target Range
Low
$6.00
Average
$6.50
High
$7.00
Current: $1.26
Latest NNVC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NNVC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2024 | EF Hutton | Tim Moore | Buy | Reiterates | $6.50 |
| Feb 16, 2024 | EF Hutton | Tim Moore | Buy | Reiterates | $6.50 |
| Jun 1, 2023 | EF Hutton | Constantine Davides | Buy | Assumes | $5.25 |
| Apr 18, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $5.25 |
| Feb 28, 2023 | EF Hutton | Constantine Davides | Buy | Maintains | $5.25 |
Nanoviricides Inc. (NNVC) Competitors
The following stocks are similar to NanoViricides based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nanoviricides Inc. (NNVC) Financial Data
Nanoviricides Inc. has a market capitalization of $27.10M with a P/E ratio of -2.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -77.5%.
Valuation Metrics
Market Cap
$27.10M
Enterprise Value
$24.43M
P/E Ratio
-2.0x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+19.0%
Current Ratio
4.4x
Debt/Equity
0.0x
ROE
-77.5%
ROA
-44.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nanoviricides Inc. (NNVC) Business Model
About Nanoviricides Inc.
What They Do
Develops antiviral therapeutics using nanotechnology.
Business Model
Nanoviricides Inc. focuses on creating novel antiviral nanomedicines called 'nanoviricides' that specifically target and neutralize virus particles. The company generates revenue by developing these innovative therapeutics for viral infections, particularly where existing treatments are lacking.
Additional Information
With its pioneering approach, Nanoviricides Inc. aims to tackle unmet medical needs in the healthcare sector, aligning with trends in precision medicine. The company's products have the potential to significantly impact public health and contribute to managing future viral outbreaks.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Dr. Anil R. Diwan Ph.D.
Country
United States
IPO Year
2005
Website
www.nanoviricides.comNanoviricides Inc. (NNVC) Latest News & Analysis
Latest News
NanoViricides seeks FDA's rare pediatric disease designation for antiviral candidate NV-387 - ICYMI
10 days ago
Quick Summary
NanoViricides has applied for rare pediatric disease designation from the FDA for its antiviral candidate NV-387, as stated by CEO Dr. Anil Diwan, emphasizing its potential scientific and commercial benefits.
Why It Matters
The FDA application for NV-387 could lead to faster approval and potential market exclusivity, enhancing NanoViricides' growth prospects and investor confidence.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
NanoViricides has applied for Rare Pediatric Disease Drug designation from the FDA for its antiviral candidate NV-387 to treat measles, alongside an earlier orphan drug request.
Why It Matters
NanoViricides' FDA application for NV-387 could enhance its market position and attract investment by addressing a significant unmet need in pediatric healthcare, potentially boosting stock value.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
NanoViricides, Inc. (NYSE American: NNVC) has filed for "Rare Pediatric Disease Drug" Designation for NV-387 as a treatment for measles, complementing a prior Orphan Drug Designation application.
Why It Matters
The RPDD application for NV-387 could lead to potential market exclusivity and financial incentives if approved, enhancing NanoViricides' valuation and growth prospects in the antiviral sector.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
NanoViricides plans to start a Phase II clinical trial for its antiviral candidate NV-387 targeting mpox in the DRC soon, with site preparations in progress.
Why It Matters
NanoViricides' Phase II trial of NV-387 for mpox could drive stock value and investor interest, indicating potential market opportunities and advancements in antiviral treatments.
Source: Proactive Investors
Market Sentiment:
Positive
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
20 days ago
Quick Summary
NanoViricides, Inc. (NNVC) will soon begin a Phase II Clinical Trial for its Monkeypox treatment, NV-387, in the Democratic Republic of Congo, with preparations being handled by Om Sai Clinical Research Pvt.
Why It Matters
The initiation of a Phase II trial for NV-387 targeting Monkeypox could enhance NanoViricides' market position and potential revenues, influencing investor sentiment and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
NanoViricides has completed manufacturing its NV-387 oral drug, an antiviral for mpox, and is ready for clinical trials pending site preparations.
Why It Matters
NanoViricides' completion of NV-387 oral drug manufacturing signals progress in its mpox clinical trial, potentially boosting investor confidence and impacting stock performance.
Source: Proactive Investors
Market Sentiment:
Positive
Frequently Asked Questions About NNVC Stock
What is Nanoviricides Inc.'s (NNVC) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Nanoviricides Inc. (NNVC) has a median price target of $6.50. The highest price target is $7.00 and the lowest is $6.00.
Is NNVC stock a good investment in 2026?
According to current analyst ratings, NNVC has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NNVC stock?
Wall Street analysts predict NNVC stock could reach $6.50 in the next 12 months. This represents a 415.9% increase from the current price of $1.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nanoviricides Inc.'s business model?
Nanoviricides Inc. focuses on creating novel antiviral nanomedicines called 'nanoviricides' that specifically target and neutralize virus particles. The company generates revenue by developing these innovative therapeutics for viral infections, particularly where existing treatments are lacking.
What is the highest forecasted price for NNVC Nanoviricides Inc.?
The highest price target for NNVC is $7.00 from at , which represents a 455.6% increase from the current price of $1.26.
What is the lowest forecasted price for NNVC Nanoviricides Inc.?
The lowest price target for NNVC is $6.00 from at , which represents a 376.2% increase from the current price of $1.26.
What is the overall NNVC consensus from analysts for Nanoviricides Inc.?
The overall analyst consensus for NNVC is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.50.
How accurate are NNVC stock price projections?
Stock price projections, including those for Nanoviricides Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:26 AM UTC